Mesenchymal tumor cells drive adaptive resistance of Trp53-/- breast tumor cells to inactivated mutant Kras.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular oncology"
DOI: 10.1002/1878-0261.13220
Abstract: As precision medicine increases the response rate of treatment, tumors frequently bypass inhibition and reoccur. In order for treatment to be effective long term, the mechanisms enabling treatment adaptation need to be understood. Here, we… read more here.
Keywords: treatment; tumor cells; krasg12d; trp53 breast ... See more keywords
Development of thymic tumor in [LSL:KrasG12D; Pdx1-CRE] mice, an adverse effect associated with accelerated pancreatic carcinogenesis
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-94566-x
Abstract: Pancreatic Ductal AdenoCarcinoma (PDAC) represents about 90% of pancreatic cancers. It is one of the most aggressive cancer, with a 5-year survival rate below 10% due to late diagnosis and poor therapeutic efficiency. This bad… read more here.
Keywords: krasg12d pdx1; krasg12d; adverse effect; lsl krasg12d ... See more keywords
KRAS mutation-induced EndMT of brain arteriovenous malformation is mediated through the TGF-β/BMP-SMAD4 pathway
Sign Up to like & getrecommendations! Published in 2022 at "Stroke and Vascular Neurology"
DOI: 10.1136/svn-2022-001700
Abstract: Objective Somatic KRAS mutations have been identified in the majority of brain arteriovenous malformations (bAVMs), and subsequent in vivo experiments have confirmed that KRAS mutation in endothelial cells (ECs) causes AVMs in mouse and zebrafish… read more here.
Keywords: krasg12d; krasg12d mutant; brain arteriovenous; tgf bmp ... See more keywords
Abstract 24: Oncogenic KrasG12D and Cdkn2a/p16 knockout in LGR5 expressing progenitor cells synergize to advance adenoma and adenocarcinoma phenotypes in murine small intestine
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-24
Abstract: Background: KRAS activating mutations are reported in 42-54% and inactivation of CDKN2A/p16 in 14-30% of human small intestinal adenocarcinomas, suggesting a role in small intestine adenocarcinogenesis. The phenotypic effects of oncogenic KRAS and p16 loss… read more here.
Keywords: krasg12d; cdkn2a p16; small intestine; progenitor cells ... See more keywords
Abstract 4481: Vrtx153, novel small molecule inhibitor of krasg12d
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4481
Abstract: Pancreatic cancer is an intractable malignancy and is the seventh leading cause of global cancer deaths in industrialized countries and the third most common in the USA. Despite advancement in the knowledge of potential risk… read more here.
Keywords: vrtx153 novel; krasg12d; inhibitor; novel small ... See more keywords
Abstract LB321: Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb321
Abstract: The RAS family of proto-oncogenes are the most frequently mutated genes in cancer, in which mutations in KRAS account for approximately 25% of all human cancers. RAS oncogenes impair the ability of RAS to convert… read more here.
Keywords: qtx3046 potent; bioavailable non; krasg12d; orally bioavailable ... See more keywords
Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-22-1013
Abstract: Inflammation is strongly associated with pancreatic ductal adenocarcinoma (PDAC), a highly lethal malignancy. Dysregulated RNA splicing factors have been widely reported in tumorigenesis, but their involvement in pancreatitis and PDAC is not well understood. Here,… read more here.
Keywords: krasg12d mediated; factor srsf1; srsf1; krasg12d ... See more keywords
USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2017-10-811760
Abstract: Ras mutations are commonly observed in juvenile myelomonocytic leukemia (JMML) and chronic myelomonocytic leukemia (CMML). JMML and CMML transform into acute myeloid leukemia (AML) in about 10% and 50% of patients, respectively. However, how additional… read more here.
Keywords: usp22 deficiency; myeloid leukemia; krasg12d; mice ... See more keywords
Discovery of potent and noncovalent KRASG12D inhibitors: Structure-based virtual screening and biological evaluation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.1094887
Abstract: KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological… read more here.
Keywords: krasg12d inhibitors; krasg12d; potent noncovalent; noncovalent krasg12d ... See more keywords